Ocular Changes in Patients Using Tirzepatide or Semaglutide

This prospective observational study aims to evaluate ocular structural and microvascular changes in adults with obesity who are receiving semaglutide or tirzepatide as part of routine clinical care. Participants with and without type 2 diabetes mellitus will be included. Participants will undergo ophthalmologic examinations at baseline and during follow-up. Changes in optic nerve head parameters, retinal thickness, retinal and choroidal microvascular parameters, and choroidal thickness will be assessed using optical coherence tomography (OCT), optical coherence tomography angiography (OCT-A), and other routine ophthalmologic examination methods. The study will compare ocular measurements obtained at baseline and during follow-up to investigate changes associated with semaglutide or tirzepatide treatment over a period of up to 18 months.

Inclusion Criteria: * Age 18 years or older * Diagnosis of obesity * Receiving semaglutide or tirzepatide as part of routine clinical care * Participants with or without type 2 diabetes mellitus * Availability for baseline and follow-up ophthalmologic examinations Exclusion Criteria: * Age under 18 years * Not receiving semaglutide or tirzepatide * Inability to complete the required ophthalmologic examinations or imaging assessments